Cola, Spotify, Starbucks, and more. From missed profits to tariff tensions, here's what investors need to know about the ...

There's no need to track down complicated and obscure businesses. Some of the market's best income-producing stocks are ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

The company expects to save an additional $1.2 billion from automation, AI and other digital tools.

Pfizer's Q1 2025 earnings call painted a picture of gritty efficiency, disciplined R&D, and a pipeline trying to hit warp ...

At Asembia’s AXS25 Summit, industry experts explored how pharmacy is evolving to meet rising patient expectations and ...

Q1 2025 Management View CEO Dr. Albert Bourla discussed Pfizer's strategic focus on improving R&D productivity, emphasizing a disciplined approach to advancing its pipeline. The company highlighted ...

Pfizer’s PFE $13.7 billion in revenue (an 8% decline) and adjusted diluted EPS of $0.92 (12% growth) allowed the firm to ...

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.